Announced details
The Company will receive a subsidy from the Ministry of Economy, Trade and Industry. The Company will establish a facility at DP-Lab KOBE, which is operated by DAIWA HOUSE INDUSTRY CO.,LTD. Capital and personnel relationships are Not disclosed.
DAIWA HOUSE INDUSTRY CO.,LTD. operates DP-Lab KOBE. Other details are Not disclosed.
Minamimachi, Chuo-ku, Kobe, Hyogo Prefecture (within DP-Lab KOBE)
Approximately ¥7 billion (grant amount)
The Company will promptly disclose the impact on results for the fiscal year ending December 2026 once it is determined. Related expenses and subsidy income are expected to be recorded primarily as research and development expenses and other income, respectively, going forward.
The company does not address Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Contract development and manufacturing organization (CDMO) business for regenerative medicine products and other products, Cell Processing Center（CPC）, HLCM051 |
| Counterparty | Ministry of Economy, Trade and Industry; DAIWA HOUSE INDUSTRY CO.,LTD. |
| Counterparty overview | DAIWA HOUSE INDUSTRY CO.,LTD. operates DP-Lab KOBE. Other details are Not disclosed. |
| Relationship with the Company | The Company will receive a subsidy from the Ministry of Economy, Trade and Industry. The Company will establish a facility at DP-Lab KOBE, which is operated by DAIWA HOUSE INDUSTRY CO.,LTD. Capital and personnel relationships are Not disclosed. |
| Contract Value | Approximately ¥7 billion (grant amount) |
| Launch date | January 2028 (scheduled start of operations) |
| Applicable area | Process development and manufacturing of regenerative medicine products and other products, Acute Respiratory Distress Syndrome (ARDS), Trauma, Acute phase of cerebral infarction, Cancer immunotherapy, Ophthalmology, Liver disease |
| Location | Minamimachi, Chuo-ku, Kobe, Hyogo Prefecture (within DP-Lab KOBE) |
| Impact on Business Performance | The Company will promptly disclose the impact on results for the fiscal year ending December 2026 once it is determined. Related expenses and subsidy income are expected to be recorded primarily as research and development expenses and other income, respectively, going forward. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish the next-generation manufacturing infrastructure being promoted as a government policy initiative and fully launch the contract development and manufacturing organization (CDMO) business for regenerative medicine products and other products.